Pricing Log in Create free account
Saturday 7 November 2026 Export KPTI’s income statement to Excel — free account

Karyopharm Therapeutics Inc.

KPTI Healthcare Biotechnology

Karyopharm Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.1 million, up 0.57% from fiscal 2024.

Revenue
−11.9%
EPS
+46.3%
Free cash flow
−33.3%
Total debt
+36.6%

Quarter to June 2026, against a year earlier

0.05 0.01 −16.67%
Market cap
$1.4M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
3/9
Altman Z
−23.89
Beneish M
−8.05
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.25
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — 2 2 3 1 6 — 1 — 1 2 —
Insider Ownership 34.86%

Capital & Financial Ratios $m

Size
Market Cap 1.36
Revenue ttm 146.62
Net income ttm (224.74)
Free cash flow ttm (65.35)
Net debt Q 184.84
Valuation
P/E 0.00
Forward P/E (0.01) (negative: loss-making)
Price / sales 0.01
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 0.79 (below 1: weak)
Debt / equity Q (0.76) (negative: negative equity)
Interest coverage Q (1.71)
Growth
Revenue growth Q −11.86% (below 0%: shrinking)
Operating income growth Q +7.63% (above 0%: growing)
EPS, this year +74.29% (at or above 15%: strong)
EPS, next year A +61.24% (at or above 15%: strong)
Revenue, next year A −7.17% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +60.92% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.3×, against a ten-year median of 4.1×; over the ten years it ranged from 0.3× in 2019 to 2,459× in 2017.
P/S against its own 10 years 0.04%
10-year low 10-year high
EV/Sales against its own 10 years 23.39%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 192 109 64 65
Receivables 27 31 26 30
Inventory 3 5 4 4
Other — — — —
234 156 103 106
2023 2024 2025 Q'26
Payables 3 5 4 8
ST’ Debt — 24 21 40
Other 2 2 2 6
69 92 92 134

Compound Annual Growth %

10y 5y 3y
Sales 89.09% 6.21% (2.39%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −1.53 Actual −2.32

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −3.30 −3.82 Miss by 0.52
Q4 FY25 −2.26 −2.23 Beat by 0.03
Q1 FY26 −1.45 −1.24 Beat by 0.21
Q2 FY26 −1.53 −2.32 Miss by 0.79
Q3 FY26 −1.05 — Reports 9 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (1.24) (2.32) — — —
’25 (2.77) (4.32) (3.82) (5.68) (17.93)
’24 (4.80) 2.31 (3.90) (3.60) (14.00)
’23 (4.50) (4.35) (4.50) (5.40) (18.74)
’22 (7.95) (9.30) (6.75) (6.45) (30.28)
’21 (11.54) (10.64) (10.34) 6.90 (24.74)
’20 (11.69) (9.45) (10.94) (8.85) (40.78)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 35 33 — — —
’25 30 38 44 34 146
’24 33 43 39 31 145
’23 39 38 36 34 146
’22 48 40 36 34 157
’21 23 23 38 126 210
’20 18 34 21 35 108
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (23) (25) — — —
’25 (39) (19) (6) (12) (75)
’24 (44) (38) (19) (26) (127)
’23 (19) (26) (30) (19) (93)
’22 (59) (35) (28) (27) (150)
’21 (53) (56) (24) 25 (107)
’20 (45) (40) (44) (31) (160)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (23) (25) — — —
’25 (39) (19) (6) (12) (75)
’24 (44) (38) (19) (26) (128)
’23 (19) (26) (30) (19) (93)
’22 (59) (35) (28) (27) (150)
’21 (53) (56) (24) 25 (107)
’20 (45) (40) (44) (31) (160)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 0 2 30 41 108 210 157 146 145 146 147 +114.2% 136 174 332 +31.5%
Gross margin, % 100.00 100.00 100.00 94.11 97.50 98.38 96.68 96.62 95.86 95.93 95.89 (4.1) pt
EBT (109) (129) (178) (200) (196) (124) (165) (143) (76) (196) (225) +6.7%
EBT margin, % (71,063.64) (8,032.46) (588.02) (487.98) (181.31) (59.01) (105.00) (97.77) (52.58) (134.18) (153.30) +70,929.5 pt
Net income (110) (129) (178) (200) (196) (124) (165) (143) (76) (196) (225) +6.7%
Per share, $
Per share, $ Revenue 0.06 0.52 8.01 9.90 22.49 41.82 28.76 19.17 17.88 13.36 5.07 +81.8%
Earnings (43.78) (42.13) (47.08) (48.28) (40.78) (24.74) (30.28) (18.74) (9.45) (17.93) (12.84) (9.4%)
Cash flow (33.72) (24.08) (42.01) (46.18) (33.35) (21.35) (27.39) (12.17) (15.69) (6.89) (2.26) (16.2%)
Capex (0.03) (0.02) (0.62) (0.05) (0.03) (0.04) (0.02) 0.00 (0.02) 0.00 0.00 n/m
Free cash flow (33.75) (24.10) (42.64) (46.23) (33.38) (21.39) (27.41) (12.17) (15.71) (6.89) (2.26) (16.2%)
Book value 64.82 42.29 48.37 12.04 10.52 (15.88) (3.05) (17.88) (22.89) (26.79) (11.41) n/m
Shares, m 3 3 4 4 5 5 5 8 8 11 18 +17.8%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 2,021.68 275.74 17.55 29.06 10.32 2.31 1.70 0.71 0.57 0.55 0.01 236.0
P/B 2.23 3.52 2.91 23.87 22.07 0.00 0.00 0.00 0.00 0.00 0.00 5.5
EV/Sales 1,297.92 186.96 10.11 25.35 9.10 2.00 1.02 0.58 1.11 1.67 1.27 153.6
EV/FCF (2.75) (4.18) (1.90) (5.43) (6.13) (3.91) (1.08) (0.92) (1.26) (3.23) (2.84) (3.1)
Cash, $m
Cash, $m Operating cash flow (84) (74) (159) (191) (160) (107) (150) (93) (127) (75) (65) (1.2%)
Capex 0 0 (2) 0 0 0 0 — 0 — 0 +9.2%
Free cash flow (84) (74) (161) (191) (160) (107) (150) (93) (128) (75) (65) (1.3%)
Balance, $m
Balance, $m Working capital 115 99 288 232 216 202 284 164 64 11 (28) (22.9%)
Net debt (130) (147) (226) (152) (132) (63) (106) (21) 79 163 185 n/m
Shareholders’ equity 162 129 183 50 51 (80) (17) (136) (186) (293) (330) n/m
Returns, %
Returns, % ROA (55.37) (71.52) (68.42) (62.75) (64.56) (40.13) (49.83) (47.81) (37.75) (143.71) (207.90) (88.3) pt
ROIC (211.70) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 +211.7 pt
ROE (60.77) (88.43) (114.13) (171.36) (391.29) 852.05 343.18 187.23 47.43 81.86 78.98 +142.6 pt
People
People Employees 108 154 332 347 432 442 385 325 279 228 — +8.7%
Revenue/emp, $m 0.00 0.01 0.09 0.12 0.25 0.47 0.41 0.45 0.52 0.64 — +97.1%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Karyopharm Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
OGEN Oragenics, Inc. $1.6M — (loss-making) — (loss-making) −75.33% (below 0%: shrinking) n/m −66.37% (below 0%: shrinking) 100.00% 0.00% Compare
KAPA Kairos Pharma, Ltd. $1.5M — (loss-making) — — n/m −25.71% (below 0%: shrinking) — 0.00% Compare
CARM Carisma Therapeutics Inc. $1.5M — (loss-making) — (loss-making) +392.01% (above 0%: growing) n/m +114.65% (above 0%: growing) 100.00% 96.83% Compare
ABPO Abpro Holdings Inc. $1.4M 0.5× — — n/m −0.48% (below 0%: shrinking) 100.00% 0.00% Compare
KPTI Karyopharm Therapeutics Inc. $1.4M — (loss-making) — (loss-making) −11.86% (below 0%: shrinking) n/m −33.34% (below 0%: shrinking) 96.75% (67.38%)
ELAB PMGC Holdings Inc. $1.3M — (loss-making) — +147.70% (above 0%: growing) n/m −44.95% (below 0%: shrinking) 29.52% (292.91%) Compare
LABT Lakewood-Amedex Biotherapeutics Inc. $1.3M — (loss-making) — — n/m −420.66% (below 0%: shrinking) — 0.00% Compare
PTIX Atrinsic Inc. $1.3M 0.2× — +34.31% (above 0%: growing) n/m +46.07% (above 0%: growing) 0.00% 0.00% Compare
BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR $1.3M — (loss-making) — −32.27% (below 0%: shrinking) +96.36% (above 0%: growing) −0.17% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $1.4M — — +34.31% — −13.09% 64.76% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 13 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 2.32m 2.12m 14.43
2024 2.07m 1.65m 19.89
2023 2.63m 35.74k 25.44

Ownership

Directors and executive officers, together 1.68%
RA Capital Management, L.P. 9.99%
T. Rowe Price Investment Management, Inc. 9.96%
Commodore Capital LP 8.65%
Affinity Healthcare Fund, LP 7.60%
Opaleye Management Inc. 6.96%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Karyopharm Therapeutics Inc. (KPTI) Latest News

4 Nov

Impact 5 · · PR Newswire

2 Nov

Impact 5 · · biopharmadive.com
Impact 5 · · InvestorsHub
Impact 5 · · PR Newswire

10 Sep

Impact 4 ·

4 Sep

Impact 3 ·

31 Aug

Impact 4 ·

21 Aug

Impact 4 ·

20 Aug

Impact 3 · · The Motley Fool transcript

14 Aug

Impact 3 · · Moby transcript

13 Aug

Impact 4 · transcript
Impact 4 ·

31 Jul

Impact 4 · · clinicaltrialsarena.com

30 Jul

Impact 4 · · Stocktwits
Impact 4 ·
Impact 4 ·

25 Jun

Impact 3 · · Simply Wall St.

14 Jun

Impact 4 ·
Impact 4 ·
Impact 4 ·

7 Jun

Impact 3 · · Simply Wall St.

2 Jun

Impact 4 · · PR Newswire
Impact 3 · · PR Newswire

26 May

Impact 4 · · MarketBeat
Impact 4 · · MarketBeat

25 May

Impact 3 · · PR Newswire

14 May

Impact 4 · · GuruFocus.com
Impact 3 · · Moby
Impact 3 · · MarketBeat
Impact 3 · · GlobeNewswire
stockrow.com/KPTI · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com